Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.
Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Morrell J, Peace S, Perez D, Rowland P, Tame CJ, Uddin S, Vitulli G, Wellaway N. Amour A, et al. Among authors: barton n. J Med Chem. 2016 Aug 11;59(15):7239-51. doi: 10.1021/acs.jmedchem.6b00799. Epub 2016 Jul 27. J Med Chem. 2016. PMID: 27429068 Free article.
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, Hessel EM. Down K, et al. Among authors: barton n. J Med Chem. 2021 Sep 23;64(18):13780-13792. doi: 10.1021/acs.jmedchem.1c01102. Epub 2021 Sep 11. J Med Chem. 2021. PMID: 34510892
Correction to Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.
Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Morrell J, Peace S, Perez D, Rowland P, Tame CJ, Uddin S, Vitulli G, Wellaway N. Amour A, et al. Among authors: barton n. J Med Chem. 2016 Sep 8;59(17):8148. doi: 10.1021/acs.jmedchem.6b01157. Epub 2016 Aug 22. J Med Chem. 2016. PMID: 27548024 No abstract available.
Correction to Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.
Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Morrell J, Peace S, Perez D, Rowland P, Tame CJ, Uddin S, Vitulli G, Wellaway N. Amour A, et al. Among authors: barton n. J Med Chem. 2016 Oct 27;59(20):9574. doi: 10.1021/acs.jmedchem.6b01461. Epub 2016 Oct 11. J Med Chem. 2016. PMID: 27726364 No abstract available.
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
Henley ZA, Amour A, Barton N, Bantscheff M, Bergamini G, Bertrand SM, Convery M, Down K, Dümpelfeld B, Edwards CD, Grandi P, Gore PM, Keeling S, Livia S, Mallett D, Maxwell A, Price M, Rau C, Reinhard FBM, Rowedder J, Rowland P, Taylor JA, Thomas DA, Hessel EM, Hamblin JN. Henley ZA, et al. Among authors: barton n. J Med Chem. 2020 Jan 23;63(2):638-655. doi: 10.1021/acs.jmedchem.9b01585. Epub 2020 Jan 8. J Med Chem. 2020. PMID: 31855425
Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ.
Spencer JA, Baldwin IR, Barton N, Chung CW, Convery MA, Edwards CD, Jamieson C, Mallett DN, Rowedder JE, Rowland P, Thomas DA, Hardy CJ. Spencer JA, et al. Among authors: barton n. ACS Med Chem Lett. 2020 Jun 3;11(7):1386-1391. doi: 10.1021/acsmedchemlett.0c00061. eCollection 2020 Jul 9. ACS Med Chem Lett. 2020. PMID: 32676144 Free PMC article.
Free-Wilson Analysis of Comprehensive Data on Phosphoinositide-3-kinase (PI3K) Inhibitors Reveals Importance of N-Methylation for PI3Kδ Activity.
Barnes L, Blaber H, Brooks DTK, Byers L, Buckley D, Byron ZC, Chilvers RG, Cochrane L, Cooney E, Damian HA, Francis L, Fu He D, Grace JMJ, Green HJ, Hogarth EJP, Jusu L, Killalea CE, King O, Lambert J, Lee ZJ, Lima NS, Long CL, Mackinnon ML, Mahdy S, Matthews-Wright J, Millward MJ, Meehan MF, Merrett C, Morrison L, Parke HRI, Payne C, Payne L, Pike C, Seal A, Senior AJ, Smith KM, Stanelyte K, Stillibrand J, Szpara R, Taday FFH, Threadgould AM, Trainor RJ, Waters J, Williams O, Wong CKW, Wood K, Barton N, Gruszka A, Henley Z, Rowedder JE, Cookson R, Jones KL, Nadin A, Smith IE, Macdonald SJF, Nortcliffe A. Barnes L, et al. Among authors: barton n. J Med Chem. 2019 Nov 27;62(22):10402-10422. doi: 10.1021/acs.jmedchem.9b01499. Epub 2019 Nov 6. J Med Chem. 2019. PMID: 31647659
A practical drug discovery project at the undergraduate level.
Fray MJ, Macdonald SJ, Baldwin IR, Barton N, Brown J, Campbell IB, Churcher I, Coe DM, Cooper AW, Craven AP, Fisher G, Inglis GG, Kelly HA, Liddle J, Maxwell AC, Patel VK, Swanson S, Wellaway N. Fray MJ, et al. Among authors: barton n. Drug Discov Today. 2013 Dec;18(23-24):1158-72. doi: 10.1016/j.drudis.2013.09.004. Epub 2013 Sep 16. Drug Discov Today. 2013. PMID: 24051399
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Procopiou PA, Barrett JW, Barton NP, Begg M, Clapham D, Copley RC, Ford AJ, Graves RH, Hall DA, Hancock AP, Hill AP, Hobbs H, Hodgson ST, Jumeaux C, Lacroix YM, Miah AH, Morriss KM, Needham D, Sheriff EB, Slack RJ, Smith CE, Sollis SL, Staton H. Procopiou PA, et al. J Med Chem. 2013 Mar 14;56(5):1946-60. doi: 10.1021/jm301572h. Epub 2013 Feb 27. J Med Chem. 2013. PMID: 23409871
517 results